Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

Por Plummer, R, Lorigan, P, Brown, E, Zaucha, R, Moiseyenko, V, Demidov, L, Soriano, V, Chmielowska, E, Andrés, R, Kudryavtseva, G, Kahatt, C, Szyldergemajn, S, Extremera, S, de Miguel, B, Cullell-Young, M, Calvert, H
Publicado em 2013

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Por Michaelson, M. D., Bellmunt, J., Hudes, G. R., Goel, S., Lee, R. J., Kantoff, P. W., Stein, C. A., Lardelli, P., Pardos, I., Kahatt, C., Nieto, A., Cullell-Young, M., Lewis, N. L., Smith, M. R.
Publicado em 2012

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

Por Calvo, E., Moreno, V., Flynn, M., Holgado, E., Olmedo, M. E., Lopez Criado, M. P., Kahatt, C., Lopez-Vilariño, J. A., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Soto Matos-Pita, A., Forster, M.
Publicado no Ann Oncol (2017)